Valuation: Black Diamond Therapeutics, Inc.

Market Cap 120M 104M 97.42M 88.89M 167M 11.45B 170M 1.14B 448M 5.73B 451M 441M 19.12B P/E 2026 *
-3.31x
P/E 2027 * -2.24x
Enterprise Value 120M 104M 97.42M 88.89M 167M 11.45B 170M 1.14B 448M 5.73B 451M 441M 19.12B EV / Sales 2026 *
16.8x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+5.56%
1 week+17.42%
Current month+23.67%
1 month+9.42%
3 months-28.91%
6 months-5.86%
Current year-13.99%
1 week 1.76
Extreme 1.76
2.1
1 month 1.62
Extreme 1.62
2.1
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
3/20/26 Free

Director

6,919 0.0121%
1/21/26 Free

Chief Technology Officer

250,000 0.4388%
1/21/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%+17.42%-9.52%-37.24% 120M
-0.70%+13.34%+75.61%+103.83% 70.51B
-0.11%-0.03%+35.48%+63.73% 54.05B
-1.62%+34.25%+17.43%+491.04% 28.95B
-1.26%+11.77%+53.59%+6.70% 24.05B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.11%+6.12%+46.81%-21.81% 18.37B
+9.77%+20.16%+260.17%+472.38% 18.67B
-0.19%+7.16%+30.57%+621.92% 16.1B
-3.08%-8.34%+37.21%+138.52% 12.72B
Average +0.83%+356.21%+53.23%+182.59% 26.68B
Weighted average by Cap. +0.03%+349.99%+57.61%+168.72%

Financials

2026 *2027 *
Net sales 7.14M 6.19M 5.79M 5.29M 9.95M 681M 10.12M 67.95M 26.62M 341M 26.82M 26.24M 1.14B -
Net income -37.69M -32.66M -30.58M -27.9M -52.5M -3.59B -53.38M -359M -140M -1.8B -142M -138M -6B -62.63M -54.28M -50.81M -46.36M -87.25M -5.97B -88.71M -596M -233M -2.99B -235M -230M -9.98B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-08-11 US$2.090 +5.56% 812,736
26-08-10 US$1.980 +1.54% 664,997
26-08-07 US$1.950 +1.56% 599,940
26-08-06 US$1.920 +7.26% 748,139
26-08-05 US$1.790 +0.56% 384,234
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.090USD
Average target price
10.00USD
Spread / Average Target
+378.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock